CN1279963C - Process for preparing product containing antiinflammatory, anticoagulant and antibacterial components from ginger and its product and medical composition - Google Patents
Process for preparing product containing antiinflammatory, anticoagulant and antibacterial components from ginger and its product and medical composition Download PDFInfo
- Publication number
- CN1279963C CN1279963C CN 01118661 CN01118661A CN1279963C CN 1279963 C CN1279963 C CN 1279963C CN 01118661 CN01118661 CN 01118661 CN 01118661 A CN01118661 A CN 01118661A CN 1279963 C CN1279963 C CN 1279963C
- Authority
- CN
- China
- Prior art keywords
- organic solvent
- thing
- liquid
- rhizoma zingiberis
- zingiberis recens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 12
- 235000006886 Zingiber officinale Nutrition 0.000 title abstract description 9
- 235000008397 ginger Nutrition 0.000 title abstract description 9
- 229940127219 anticoagulant drug Drugs 0.000 title abstract description 3
- 241000234314 Zingiber Species 0.000 title abstract 2
- 239000007788 liquid Substances 0.000 claims abstract description 53
- 239000003960 organic solvent Substances 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 24
- 238000005406 washing Methods 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims abstract description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 239000000047 product Substances 0.000 claims description 29
- 239000012141 concentrate Substances 0.000 claims description 23
- 238000000638 solvent extraction Methods 0.000 claims description 20
- 241000555688 Malassezia furfur Species 0.000 claims description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 17
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims description 14
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims description 14
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- 208000002474 Tinea Diseases 0.000 claims description 13
- 239000006210 lotion Substances 0.000 claims description 13
- 241000130764 Tinea Species 0.000 claims description 12
- 238000004821 distillation Methods 0.000 claims description 11
- 206010030113 Oedema Diseases 0.000 claims description 10
- 206010040943 Skin Ulcer Diseases 0.000 claims description 10
- 230000000702 anti-platelet effect Effects 0.000 claims description 10
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 10
- 125000005594 diketone group Chemical group 0.000 claims description 10
- 231100000019 skin ulcer Toxicity 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 claims description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- 230000008676 import Effects 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 21
- 244000273928 Zingiber officinale Species 0.000 abstract description 7
- 239000001841 zingiber officinale Substances 0.000 abstract description 7
- 238000004587 chromatography analysis Methods 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract 2
- 241000220317 Rosa Species 0.000 abstract 1
- 229960001701 chloroform Drugs 0.000 abstract 1
- 238000001256 steam distillation Methods 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 7
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000001840 Dandruff Diseases 0.000 description 5
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 5
- 208000008742 seborrheic dermatitis Diseases 0.000 description 5
- 239000003637 basic solution Substances 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 238000007667 floating Methods 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 201000004647 tinea pedis Diseases 0.000 description 4
- VBKDALTZEUBYTQ-RBMCBPMHSA-N Dehydrogingerdione Chemical compound COc1cc(\C=C\C(\O)=C/C(C)=O)ccc1O VBKDALTZEUBYTQ-RBMCBPMHSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 210000003056 antler Anatomy 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000002780 gingerol Nutrition 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 3
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- 241000101040 Pityriasis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007712 Tinea Versicolor Diseases 0.000 description 2
- 206010043866 Tinea capitis Diseases 0.000 description 2
- 206010056131 Tinea versicolour Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000012675 alcoholic extract Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000144987 brood Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 201000005882 tinea unguium Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- FZWNRFAUDBWSKY-QNQPVOBRSA-N (1e,3z)-3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)deca-1,3-dien-5-one Chemical compound CCCCCC(=O)\C=C(/O)\C=C\C1=CC=C(O)C(OC)=C1 FZWNRFAUDBWSKY-QNQPVOBRSA-N 0.000 description 1
- VEMLQICWTSVKQH-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;propane-1,2,3-triol Chemical compound OCC(O)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VEMLQICWTSVKQH-BTVCFUMJSA-N 0.000 description 1
- JUKHKHMSQCQHEN-VQHVLOKHSA-N 1-Dehydro-[6]-gingerdione Natural products CCCCCC(=O)CC(=O)\C=C\C1=CC=C(O)C(OC)=C1 JUKHKHMSQCQHEN-VQHVLOKHSA-N 0.000 description 1
- LSVICRMDTZSTDC-UHFFFAOYSA-N 2-acetyloxybenzoic acid Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O LSVICRMDTZSTDC-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 208000005005 intertrigo Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a method for preparing antiinflammation, anticoagulant and antibacterial active ingredients from ginger. The present invention comprises the following steps that rough liquid is prepared by organic solvent or supercritical carbon dioxide extraction or steam distillation by Zingiber officinale Rose. The rough liquid is led to an inverse phase chromatography pipe column, and water, first flow washing liquid and second flow washing liquid are orderly led for washing in a flow way. Milking products of the first flow washing liquid and milking products of the second washing liquid are collected, wherein the polarity of the first flow washing liquid is larger than that of the second flow washing liquid, and the polarity of the second flow washing liquid is larger than that of trichloromethane. The first flow washing liquid and the second flow washing liquid are volatilized and removed from the milking products, and the milking products for serving as first concentration milking products and second concentration milking products of the active ingredients are obtained.
Description
The invention relates to a kind of method that from Rhizoma Zingiberis Recens, prepares the product of the effective ingredient that contains anti-inflammatory, anti-platelet aggregation or antibacterial activity.
In China or Japanese, Rhizoma Zingiberis Recens edible or medicinal aspect all be very general material.Rhizoma Zingiberis Recens is a seasoning condiment indispensable in general common people's daily life, clinical the be used for dispersing wind-cold, arresting vomiting by invigorating the stomach of the traditional Chinese medical science more, detoxifcation, Sucus Zingberis can be used as external application, has effect (the clinical practice science of color Chinese medicine grand ceremony of anti-inflammatory analgetic, first of international Chinese edition, 76 pages, Li De publishing house).In Saudi Arabia, Jiang Ze be used for the treatment of vomiting, facilitating digestion or as carminative (Ageel et al, 1987, Plants Usedin Saudi Folk Medicine, King Saud University Press, Riyadh, p.400).
In recent years, many scientific researches demonstrate Rhizoma Zingiberis Recens and have physiologically active widely.For example: the compound recipe that contains Rhizoma Zingiberis Recens can suppress cancer metastasis (Japanese patent publication 07258104), antiviral (Japanese patent publication 0711861), the generation of auxiliary nervous trophic factors, improves brain diseasess such as Alzheimer disease and Parkinson's disease (Japanese patent publication 07025777), arthritis (Japanese patent publication 06293653, No. the 5494668th, United States Patent (USP), No. the 5683698th, United States Patent (USP)), antimicrobial (Japanese patent publication 06227931), analgesia (Japanese patent publication 06107556) etc.In fact, Rhizoma Zingiberis Recens contains 1～4% volatile oil, wherein has 200 kinds of materials to be separated approximately.Mention in No. the 5804603rd, United States Patent (USP), Jiang Suohan zingiberone (zingerone) is the main source of acid, and zingiberol (gingerol) also has hot fragrance with shogaol (shogaol).In addition, zingiberol has heart tonifying, suppresses the effects such as contraction that the stripped vein contraction of mouse, regulation and control mouse and rabbit blood vessel cause because of eicosanoid, and shogaol then can suppress vasoconstriction.Show that in the research of Srivastava and Mustafa Rhizoma Zingiberis Recens can suppress epoxidation ferment (cyclooxygenase) and generate with lipid oxidation ferment (lipoxygenase) product, synthetic (the Medical Hypotheses that suppresses eicosanoid simultaneously, 1992,39:342-348).MascoloN. wait the people then to find, after oral dose administration with 100mg/kg, 80% alcoholic extract of Rhizoma Zingiberis Recens and acetylsalicylic acid (acetylsalicylic acid) are suitable to the inhibition effect of the mouse sole edema that antler glue (carageenan) brings out, and suppression ratio is respectively 39% and 38%.Find also that in same research 80% alcoholic extract of Rhizoma Zingiberis Recens can suppress the caused heating of yeast, and can suppress gram-negative bacteria and gram-positive bacteria growth (Journal of Ethnopharmocology, 1989,27,129-140).Srivastava and Mustafa are with 56 clinical patients of Rhizoma Zingiberis powder end treatment, the result shows that 3/4ths arthritis patient eases the pain or swelling, and the patient of all muscle discomforts all feels pain alleviate, and at three months during two-and-a-half years clinical, do not have patient table be shown with ill effect produce (1992, ibid).
Dermatophytes (Dermatophytes), especially trichophyton purpureatum (Trichophyton rubrum) reaches and sends out skin ulcer budlet spore tinea bacterium (Trichophyton mentagrophytes), common cause of disease [Roberts DT. for mycosis ungualis (onychomycosis) and tinea pedis (tinea pedis), British Journal of Dermatology.141 Supple 56:1-4,1999 Nov.; Roldan YB.et al., Mycoses, 43 (5): 181-3,2000].Pityrosporum ovale [Pityrosporum ovale (Malasseziafurfur)] is the cause of disease that tinea versicolor (pityriasis vesicolor), skin brood cell bacterium filter born of the same parents' inflammation (Pityrosporum folliculitis) and the peppery plug of horse Salmonella are wiped rash (Malassezia intertrigo).Existing several studies show that pityrosporum ovale (Pityrosporum ovale) relevant with the seborrheic dermatitis (seborrheic dermatitis) and the dandruff (dandruff belongs to a kind of seborrheic dermatitis of light symptom) [Nenoff P.et al., Dermatology.191 (4): 311-4,1995; Bulmer AC.et al., Mycopathologia, 147 (2) 63-5,1999].
The present invention utilizes organic solvent (ether, acetone, methanol, ethanol) or supercritical carbon dioxide extraction, or prepare a rough liquid from Rhizoma Zingiberis Recens (Zingiber officinale) rhizome with vapor distillation, refining and obtain containing the product of shogaol (shogaols), zingiberol (gingerols) and/or dehydrogenation Rhizoma Zingiberis Recens diketone (dehydrogingerdione) through the reverse-phase chromatography method again.These products confirm to have certain activity through external anti-platelet aggregation test, and then confirm to have the swollen effect of tangible anti-floating, and has tangible antibacterial activity by the activity assessment confirmation that suppresses to send out skin ulcer budlet spore tinea bacterium (Trichophytonmentagrophytes) and pityrosporum ovale (Pityrosporum ovale) through the animal experiment of antler glue (Carrageenan) method.
As described in background, Sucus Zingberis has the record of antiinflammatory, pain relieving effectiveness.
The present invention aims to provide a kind of effective method is provided the effective ingredient of anti-inflammatory, anti-platelet aggregation and antibacterial activity from the preparation of Rhizoma Zingiberis Recens rhizome product, and prepared product has effective component contents such as fixed in fact, thereby has clear and definite pharmacological action.
A kind ofly contain the method for product of the effective ingredient of anti-inflammatory, anti-platelet aggregation or antibacterial activity fully according to what content of the present invention was finished, comprise the following step from processed with Rhizoma Zingiberis Recens:
A) prepare a rough liquid from Rhizoma Zingiberis Recens (Zingiber officinale) rhizome;
B) should import a reverse-phase chromatography tubing string by rough liquid, and wash with water, first-class washing liquid and the second flowing lotion stream in regular turn, molten molten from the thing and second flowing lotion of collecting wherein first-class washing liquid from thing, wherein the polarity of this first-class washing liquid is greater than this second flowing lotion, and the polarity of this second flowing lotion is greater than chloroform; And
C) volatilization remove this first-class washing liquid molten in thing first-class washing liquid and one first concentrate moltenly from thing, this first concentrates and moltenly can be used as this product from thing and be removed; And
D) volatilization remove this second flowing lotion molten in thing second flowing lotion and one second concentrate moltenly from thing, this second concentrates and moltenly can be used as this product from thing and be removed,
Wherein this step a) comprises the following step i) extremely iv), step I), step I ') or step I "), this step I) to iv) being:
I) the fresh rhizome of Rhizoma Zingiberis Recens (Zingiber officinale) is pulverized and filtered, and obtain filtrate and residue part;
Ii) with this filtrate with one first organic solvent extraction, take out the first organic solvent extraction liquid obtained, and volatilization removes first organic solvent wherein and obtains spissated first an organic solvent extraction liquid;
Iii) with this residue partly with one second organic solvent extraction, take out the second organic solvent extraction liquid that is obtained, and volatilization removes second organic solvent wherein and obtains spissated second an organic solvent extraction liquid; And
Iv) merge this spissated first organic solvent extraction liquid and this spissated second organic solvent extraction liquid and obtain this rough liquid;
This step I) be:
I) with the dry rhizome of the pulverized Rhizoma Zingiberis Recens of this second organic solvent extraction (Zingiber officinale), take out the second organic solvent extraction liquid that is obtained, and volatilization removes second organic solvent wherein and obtains this rough liquid;
This step I ') be:
I ') with the dry rhizome of the pulverized Rhizoma Zingiberis Recens of vapor distillation (Zingiber officinale), the distillation that concentrating under reduced pressure obtained and obtain this rough liquid; And
This step I ") be:
I ") with the dry rhizome of the pulverized Rhizoma Zingiberis Recens of supercritical carbon dioxide extraction (Zingiber officinale), and volatilization removes carbon dioxide wherein and obtains this rough liquid.
Comprise the shogaol (shogaol) of 0-10mg/g, the 6-dehydrogenation Rhizoma Zingiberis Recens diketone (6-dehydrogingerdione) of the zingiberol of 1-150mg/g (gingerol) and 0-40mg/g according to this prepared product that contains the effective ingredient of anti-inflammatory, anti-platelet aggregation or antibacterial activity of the inventive method.
The present invention also provides a kind of medical component with anti-inflammatory activity, anti-platelet aggregation activity or antibacterial activity, comprise the prepared rough liquid of the step a) according to aforementioned the inventive method of anti-inflammatory treatment effective dose as effective ingredient, and pharmaceutically acceptable carrier or diluent.
The present invention also provides a kind of medical component with anti-inflammatory activity, anti-platelet aggregation activity or antibacterial activity, comprises to comply with the prepared product of aforementioned the inventive method as effective ingredient, and pharmaceutically acceptable carrier or diluent.Preferably, this product be this first concentrate molten from thing.Optionally, this product be this second concentrate molten from thing.
Preferably, this first-class washing liquid is that methanol and this second flowing lotion are acetone.
Preferably, this step a) comprises step I) extremely iv).
Preferably, this first organic solvent is an ether.
Preferably, this second organic solvent is acetone, methanol, ethanol or their mixture.More preferably, this second organic solvent is an acetone.
Preferably, this step a) comprises step I).
Optionally, this step a) comprises step I ').
Optionally, this step a) comprises step I ").
Be applicable to that the reverse-phase chromatography tubing string of the inventive method includes, but is not limited to be filled with the resin of porous polymer, for example Diaion HP-20 (Mitsubishi Mitsubishi Co.), SephadexLH-20 (Pharmicia Co.) or RP-18 reverse-phase chromatography resins such as (Nacalai tesque Co.).
Medical component with antibacterial activity of the present invention preferably is employed partly, and for example the form with shampoo, bath oil, soap, body lotion, health cream and abluent is used.Preferable, be used to treatment and send out skin ulcer budlet spore tinea bacterium (Trichophyton mentagrophytes) and pityrosporum ovale (Pityrosporum ovale) diseases associated, include but not limited to tinea pedis (tineapedis), tineatonsurans (tinea capitis), epidermophytosis inguinale (tinea cruris), sliding tinea (tinea glabrosa), mycosis ungualis (onychomycosis), tinea capitis (pityriasis capitis), tinea versicolor (pityriasisvesicolor), skin brood cell bacterium filter born of the same parents' inflammation (Pityrosporum folliculitis), seborrheic dermatitis (seborrheic dermatitis), and the dandruff (dandruff).Especially the medical component with antibacterial activity of the present invention is one to be used for the treatment of the shampoo form of the dandruff.
Below in conjunction with embodiment technical scheme of the present invention is further described, but illustrated embodiment only for explanation but not be used to limit the scope of the invention.
The mensuration of effective ingredient:
In following examples, use high performance liquid chroma-tography (high performance liquidchromatography is called for short HPLC) to measure the effective ingredient of the prepared product of the inventive method.HPLC spectrum is to be recorded in a high-performance liquid chromatograph (HPLC Shimadzu LC-10AT, Japan), wherein an amount of sample is with mobile phase solution [formonitrile HCN and water (65: 35, V/V) mixed liquor] quantitatively to 25ml, behind 0.25 μ m membrane filtration, filtrate injection one is filled with tubing string (long 25cm, the internal diameter 4.6mm of Cosmosil 5C-18, particle size 5 μ m), carry out stream with this mobile phase solution and wash (elution).(Shimadzu SPD-6AV Japan), detects the absorption of eluat (eluate) at wavelength 230nm to adopt UV-detector.
Embodiment 1
Rhizoma Zingiberis Recens 2100g is smashed after-filtration get filtrate and Rhizoma Zingiberis Recens residue.Get 500ml filtrate with 500ml extracted with diethyl ether three times, the water layer that extraction is at every turn obtained separates with ether layer, merges separated ether layer, volatilization remove wherein ether and must ether layer concentrate (I-OE).In addition with the Rhizoma Zingiberis Recens residue with 3000ml acetone extract three times, after the filtration acetone extract liquid, will extract at every turn and obtain that acetone extract liquid merges and concentrating under reduced pressure gets acetone extract (I-O) 14.5g.To get 7g after ether layer concentrate (I-OE) and acetone extract (I-O) merging, injection one is filled with anti-phase chromatograph chromatography tubing string (the length 30cm of 180g Diaion HP-20 resin, internal diameter 3cm, particle diameter 500 μ m-800 μ m), in regular turn with 1500ml water, 2500ml methanol, 2000ml acetone and 2000ml chloroform carry out stream and wash (elution), collect water-soluble from thing, methanol is molten from thing, acetone is molten molten from thing from thing and chloroform, must concentrate water-soluble from thing (I-OW) 0.27g behind the concentrating under reduced pressure, it is molten from thing (I-OM) 1.45g to concentrate methanol, it is molten molten from thing (I-OC) 0.83g from thing (I-OA) 2.68g and concentrated chloroform to concentrate acetone.Wherein, the content of 6-shogaol, 6-zingiberol and 6-dehydrogenation Rhizoma Zingiberis Recens diketone is as shown in Table 1 among I-O, I-OM and the I-OA.
Table one
| Content (mg/g) | I-O | I-OM | I-OA |
| 6-shogaol 6-zingiberol 6-dehydrogenation Rhizoma Zingiberis Recens diketone | 1.10±0.14 59.98±0.99 7.68±0.42 | 1.15±0.0 103.37±8.57 8.94±0.41 | - 2.51±0.89 - |
Embodiment 2
Directly divide three extractions (each 10L) after Rhizoma Zingiberis 500g smashed with 30L acetone, after the filtration acetone filtrate, merging filtrate and concentrating under reduced pressure get acetone extract (II-O) 24g.Get the 20g acetone extract, by filling the anti-phase chromatograph chromatography tubing string of 600g DiaionHP-20 resin, wash with 4L water, 6.5L methanol, 15L acetone and 5L chloroform stream in regular turn, collect water-soluble molten molten molten from thing from thing and chloroform from thing, acetone from thing, methanol, must concentrate behind the concentrating under reduced pressure respectively water-soluble from thing (II-OW) 2.5g, concentrate methanol molten from thing (II-OM) 7.1g, to concentrate acetone molten molten from thing (II-OC) 3.5g from thing (II-OA) 6.9g and concentrated chloroform.Wherein, the content of 6-shogaol, 6-zingiberol and 6-dehydrogenation Rhizoma Zingiberis Recens diketone is as shown in Table 2 among II-O, II-OM and the II-OA.
Table two
| Content (mg/g) | U-O | II-OM | II-OA |
| 6-shogaol 6-zingiberol 6-dehydrogenation Rhizoma Zingiberis Recens diketone | 1.98±0.00 43.06±0.84 9.33±0.85 | 4.96±0.00 70.87±1.85 19.15±4.57 | - 2.54±0.00 2.35±0.28 |
Embodiment 3
Rhizoma Zingiberis 10kg is smashed the back with vapor distillation 5 hours, the distillation concentrating under reduced pressure is got distillation (III-O) 410g.Get the 20g distillation by filling the anti-phase chromatograph chromatography tubing string of 600g Diaion HP-20 resin, wash with 4.5L water, 4.5L methanol, 3L acetone and 5L chloroform stream in regular turn, collect water-soluble molten molten molten from thing from thing and chloroform from thing, acetone from thing, methanol, must concentrate behind the concentrating under reduced pressure water-soluble from thing (III-OW) 0.03g, concentrate methanol molten from thing (III-OM) 14.5g, to concentrate acetone molten molten from thing (III-OC) 0.2g from thing (III-OA) 0.85g and concentrated chloroform.The vapor distillation thing (III-O) of Rhizoma Zingiberis is analyzed through HPLC and is not contained 6-shogaol, 6-zingiberol and 6-dehydrogenation Rhizoma Zingiberis Recens diketone.
Embodiment 4
Get 10g pulverize Rhizoma Zingiberis with 1000ml acetone in 50 ℃ of extractions 2 hours, remove by filter plant residue, behind the concentrating under reduced pressure with vacuum drying (40 ℃, 75mmHg vacuum) acetone extract thing IV-O.The color and luster and the viscosity of productive rate and product see Table three.
Embodiment 5
Get 10g and pulverize Rhizoma Zingiberis, with its oil-soluble and the lyophilization of water solublity extraction part, get oil-soluble extract V-O and water-soluble extract V-W respectively with vapor distillation.The color and luster and the viscosity of productive rate and product see Table three.
Embodiment 6
Get 10g and pulverize the extraction tank that Rhizoma Zingiberis places volume 250ml, with high pressure group Pu (EK-1 of LEWA company type, the U.S.) control supercritical CO
2Pressure, setting pressure are 2500 to 4000psia, and temperature cooperates the control of extraction tank external circulation line by heat exchanger (H-2410 of HOTEC company type, Taiwan), keeps operative temperature at 35-60 ℃, and flow speed control is worked as CO at 45L/min
2When volume reaches 300L, stop extraction step, get extract VI-O.The color and luster and the viscosity of productive rate and product see Table three, and the pungent component content of product sees Table four.
Table three
| IV-O | V-O | VI-O | |
| L * A * B * | 87.6 -9.1 31.1 | 80.4 -0.1 9.6 | 96.3 -9.6 22.0 |
| Viscosity (cPs) | 15.6 | 11.8 | 12.1 |
| Productive rate (%) | 3.8 | 2.2 | 3.9 |
*: the value of L, A, B be with colour difference meter (∑ 90 color measuring system, Nippon DenshokuInc, co., LTD Japan) measures, lightness represents that with L colourity is represented with A and B.
Table four
| Content (mg/g) | VI-O |
| 6-shogaol 6-zingiberol 6-dehydrogenation Rhizoma Zingiberis Recens diketone | 17.30±0.00 26.29±0.00 19.20±1.19 |
The pharmacologically active assessment of embodiment 7 anti-platelet aggregations
With EDTA (100mM) is anticoagulant, by rabbit ear vein blood drawing (1: 14), with blood after under 90 * g centrifugal 10 minutes, get the upper strata and be rich in platelet blood plasma under 500 * g centrifugal 10 minutes, after removing upper plasma, with platelet suspension in calcic not but contain Tyrode ' the s solution of 2mM EDTA, again under 500 * g centrifugal 10 minutes subsequently, after removing Tyrode ' s solution, platelet is suspended in again Tyrode ' the s solution that does not contain EDTA, and centrifugal through above-mentioned condition, at last with platelet suspension (mM): NaCl (138.6) in the buffer of following composition, KCl (2.8), NaHCO
3(11.9), MgCl
2(1.1), NaH
2PO
4(0.33), CaCl
2(1.0), glycerol (glucose) (11.2) and bovine serum albumin (0.35%), PC then is adjusted in every ml buffer and contains 4.5 * 10
8Individual platelet.The results are shown in table five.
Table five, Rhizoma Zingiberis Recens extract cause the inhibitory action of platelet aggregation to arachic acid and collagen protein
A)
| The Rhizoma Zingiberis Recens extract b) | Suppress the required concentration of 50% agglutination (μ g/ml) | |
| Arachic acid | Collagen protein | |
| I-O I-OM II-O II-OA II-OC II-OM | 3.8±0.8 1.7±0.3 3.1±0.5 10.9±3.2 6.9±0.7 2.0±0.2 | 5.5±0.4 2.7±0.4 6.5±1.2 21.8±2.2 16.6±4.3 6.9±2.4 |
A)With platelet and solvent or Rhizoma Zingiberis Recens extract 37 ℃ warm 3 minutes down, add arachic acid (100 μ M) subsequently or collagen protein (10 μ g/ml) causes platelet aggregation, after 6 minutes when reaction when reaching maximum, record platelet aggregation degree, extract calculates in the following manner to hematoblastic inhibition percentage ratio:
The n value of data is 3 to 5 in [(control group coagulation degree-experimental group coagulation degree)/(control group coagulation degree)] * 100% table.
B)Preparation among the embodiment 1 and 2
The bullate pharmacologically active assessment of embodiment 8 anti-floatings
The swollen activity of anti-floating is according to Winter, and people's such as C.A. method is assessed (Winter C.A.etal., Proc.Soc.Exper.Biol.Med.111:544-547,1962.), and it thes contents are as follows:
After the public Wistar rat fasting overnight with 150 ± 20g, squeeze into antler glue (Carrageenan) (o.1ml at the left foot palm, 1% suspension (suspension)), immediately solvent or testing sample (10mg/paw) are evenly spread upon on the left back sole, after three hours, the hind paw volume is with plethysmograph (Cat.#7150, UGO Basil, Italy) measured, and deducted the pointer of right crus of diaphragm palm volume as the edema degree with left foot palm volume.
The anti-floating of table six, Rhizoma Zingiberis Recens extract is swollen active
A)
| Handle b) | Dosage (mg/paw) | Edema suppresses (%) (Inhibition on carrageenan edema) |
| I-O I-OE I-OM I-OA | 10 10 10 10 | 18 19 29 25 |
| II-O II-OW II-OM II-OA II-OC | 10 10 10 10 10 | 18 0 26 25 8 |
| III-O III-OM III-OA | 10 10 10 | 0 11 15 |
| [6]-dehydrogingedione | 5 | 26 |
A). the percentage ratio that suppresses edema calculates in the following manner:
[(control group mouse edema degree)-(experimental group mouse edema degree)/(control group mouse edema degree)] * 100%
Data are the meansigma methods of 3 to 6 mouse in the table.
B)Preparation among the embodiment 1,2 and 3
Embodiment 9 suppresses to send out the activity assessment of skin ulcer budlet spore tinea bacterium (Trichophyton mentagrophytes) and pityrosporum ovale (Pityrosporum ovale)
To sending out the inhibiting assessment of skin ulcer budlet spore tinea bacterium
The Rhizoma Zingiberis Recens extract is to sending out skin ulcer budlet spore tinea bacterium (Trichophyton mentagrophytes; ATCC9533) inhibitory action is according to Edwards, J.R. wait people's method to be assessed (Edwards, J.R.etal., Antimicrobial Agents Chemotherapy 33:215-222,1989), and with minimal inhibitory concentration represent (minimum inhibitory concentration; MIC), the Rhizoma Zingiberis Recens extract is become the basic solution (stock solution) of various desired concns with dimethyl sulfoxide (dimethyl sulfoxide is called for short DMSO) dissolving back redilution.0.01 milliliter of basic solution added contain 0.99 milliliter of potato glucose nutritional solution [Potato Dextrose Broth (DIFCO, U.S.A.)] with 10
3To 10
4CFU/ml sends out in the 48 hole culture plates of skin ulcer budlet spore tinea bacterium, culture plate is inspected the decision extract with naked eyes after 28 ℃ down temperature is bathed 72 hours inhibitory action, and as the blank group, each test is all carried out in two multiple modes in the experiment and with solvent.The result as shown in Table 7.
Inhibitory action to pityrosporum ovale
The Rhizoma Zingiberis Recens extract is to pityrosporum ovale (Pityrosporum ovale; ATCC 38593) inhibitory action also according to above-mentioned Edwards, people's such as J.R. method is assessed, and represents (minimum inhibitory concentration with minimal inhibitory concentration; MIC), the Rhizoma Zingiberis Recens extract is become the basic solution of desired concn with DMSO dissolving back redilution.0.01 milliliter of basic solution added contain in 0.99 milliliter of flow-like Sa Pu Rockwell medium [Fluid Sabouraud Medium (DIFCO, U.S.A.)] with 10
3-10
4In the 48 hole culture plates of CFU/ml pityrosporum ovale, after 37 ℃ down temperature was bathed 48 hours, with the inhibitory action of macroscopy decision extract, as the blank group, each test was all carried out in two multiple modes in the experiment and with solvent DMSO.The result as shown in Table 7.
Table seven Rhizoma Zingiberis Recens extract is to the inhibitory action of a pityrosporum ovale (Pityrosporum ovale) and a skin ulcer budlet spore tinea bacterium (Trichophyton mentagrophytes)
| The Rhizoma Zingiberis Recens extract a) | MIC(μg/ml) | |
| Pityrosporum ovale | Send out skin ulcer budlet spore tinea bacterium | |
| I-O | 100 | 30 |
| I-OM | 100 | 30 |
| II-O | 500 | 30 |
| II-OC | 100 | 30 |
| II-OM | 100 | 30 |
| III-O | 500 | 100 |
| The blank group | -- b) | -- b) |
A)Prepared at embodiment 1,2 and 3
B)The unrestraint effect
Claims (10)
1. one kind contains the method that zingiberol and selectivity contain the product of the anti-inflammatory edema of shogaol or dehydrogenation Rhizoma Zingiberis Recens diketone or anti-platelet aggregation fully from processed with Rhizoma Zingiberis Recens, comprises the following step:
A) prepare a rough liquid from the Rhizoma Zingiberis Recens rhizome;
B) should import a reverse-phase chromatography tubing string by rough liquid, and wash with water, first-class washing liquid and the second flowing lotion stream in regular turn, molten molten from the thing and second flowing lotion of collecting wherein first-class washing liquid from thing, wherein this first-class washing liquid is a methanol, this second flowing lotion is an acetone; And
C) volatilization remove this first-class washing liquid molten in thing first-class washing liquid and one first concentrate moltenly from thing, this first concentrates and moltenly can be used as this product from thing and be removed; And
D) volatilization remove this second flowing lotion molten in thing second flowing lotion and one second concentrate moltenly from thing, this second concentrates and moltenly can be used as this product from thing and be removed,
Wherein this step a) comprises the following step i) extremely iv), step I), step I ') or step I "), this step I) to iv) being:
I) the fresh rhizome of Rhizoma Zingiberis Recens is pulverized and filtered, and obtain filtrate and residue part;
Ii) with this filtrate with one first organic solvent extraction, take out the first organic solvent extraction liquid obtained, and volatilization removes first organic solvent wherein and obtains spissated first an organic solvent extraction liquid;
Iii) with this residue partly with one second organic solvent extraction, take out the second organic solvent extraction liquid that is obtained, and volatilization removes second organic solvent wherein and obtains spissated second an organic solvent extraction liquid; And
Iv) merge this spissated first organic solvent extraction liquid and this spissated second organic solvent extraction liquid and obtain this rough liquid;
This step I) be:
I) with the dry rhizome of the pulverized Rhizoma Zingiberis Recens of this second organic solvent extraction, take out the second organic solvent extraction liquid that is obtained, and volatilization removes second organic solvent wherein and obtains this rough liquid; And
This step I ') be:
I ') with the dry rhizome of the pulverized Rhizoma Zingiberis Recens of vapor distillation, the distillation that concentrating under reduced pressure obtained and obtain this rough liquid; And
This step I ") be:
I ") with the dry rhizome of the pulverized Rhizoma Zingiberis Recens of supercritical carbon dioxide extraction, and volatilization removes carbon dioxide wherein and obtains this rough liquid.
2. the method for claim 1, wherein this product comprises the shogaol of 0-10mg/g, the 6-dehydrogenation Rhizoma Zingiberis Recens diketone of the zingiberol of 1-150mg/g and 0-40mg/g.
3. the method for claim 1, wherein this first organic solvent is an ether.
4. the method for claim 1, wherein this second organic solvent is acetone, methanol, ethanol or their mixture.
5. the method for claim 1, reverse-phase chromatography tubing string wherein is filled with the resin of porous polymer.
6. the purposes of anti-inflammatory edema medicine is made in a use according to the prepared product of the described method of claim 1.
7. the purposes of the medicine of the platelet aggregation that anti-arachic acid and collagen protein cause is made in a use according to the prepared product of the described method of claim 1.
8. a use is according to the anti-purposes of sending out the medicine of the disease that skin ulcer budlet spore tinea bacterium and pityrosporum ovale cause of the prepared product manufacturing treatment of the described method of claim 1.
9. as claim 6,7 or 8 described purposes, product wherein be this first concentrate molten from thing.
10. as claim 6,7 or 8 described purposes, product wherein be this second concentrate molten from thing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01118661 CN1279963C (en) | 2001-06-07 | 2001-06-07 | Process for preparing product containing antiinflammatory, anticoagulant and antibacterial components from ginger and its product and medical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01118661 CN1279963C (en) | 2001-06-07 | 2001-06-07 | Process for preparing product containing antiinflammatory, anticoagulant and antibacterial components from ginger and its product and medical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1390565A CN1390565A (en) | 2003-01-15 |
| CN1279963C true CN1279963C (en) | 2006-10-18 |
Family
ID=4663347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01118661 Expired - Lifetime CN1279963C (en) | 2001-06-07 | 2001-06-07 | Process for preparing product containing antiinflammatory, anticoagulant and antibacterial components from ginger and its product and medical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1279963C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100431652C (en) * | 2003-06-25 | 2008-11-12 | 绿益康生物科技实业股份有限公司 | Process and device for the separation of natural articles |
| IT1401141B1 (en) * | 2010-07-26 | 2013-07-12 | Indena Spa | FORMULATIONS CONTAINING EXTRACTS OF ECHINACEA ANGUSTIFOLIA AND ZINGIBER OFFICINALE USEFUL IN THE REDUCTION OF INFLAMMATION AND PERIPHERAL PAIN |
| MX2017007990A (en) * | 2014-12-19 | 2018-08-01 | Paradise Health Inc | Methods for reducing platelet aggregation and treating cardiovascular disease and other medical disorders. |
-
2001
- 2001-06-07 CN CN 01118661 patent/CN1279963C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1390565A (en) | 2003-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4052819B2 (en) | Method for producing extract containing ginger active ingredient, and pharmaceutical composition containing the extract | |
| CN1279963C (en) | Process for preparing product containing antiinflammatory, anticoagulant and antibacterial components from ginger and its product and medical composition | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN105125620A (en) | Caesalpinia decapetala extract and preparing method and medical application thereof | |
| CN1299702C (en) | Preparation of medicine preparation of orthopedics department and its use | |
| US6946153B2 (en) | Anti-fungal pharmaceutical compositions comprising an active ingredient prepared from Zingiber officinale | |
| CN1748772A (en) | Acne removing preparation and new preparing method | |
| CN1772272A (en) | Food antibiotic and its prepn | |
| CN1283391A (en) | Extracted liquor for disinfection | |
| CN1698587A (en) | Total diterpene phenol originated from rosemary, its preparation method and use | |
| JP5773997B2 (en) | Method for isolating Shimiracemart A | |
| CN101028356A (en) | Antiseptic anti-inflammatory and its production | |
| CN1742926A (en) | Zuoci preparation for deaf and new preparing method thereof | |
| CN1258368C (en) | Medicine for curing hyperthermia and its prepn | |
| CN1824128A (en) | Semen locking medicinal preparation and its new preparation method | |
| CN1291738C (en) | Anti-phlogistic anti-viral medicine compositon and technique for preparing the same | |
| CN1803155A (en) | Medicine for curing rhinitis | |
| CN1269522C (en) | Traditional Chinese medicine for treating cancer and its preparation method | |
| CN114010694B (en) | Preparation method of siberian cocklour and magnolia bark oral liquid | |
| CN108478639B (en) | Traditional Chinese medicine composition for treating/preventing poultry Ankara disease and preparation method and application thereof | |
| CN1557824A (en) | Silkworm excrement total alkaloid and its preparation method | |
| CN1451382A (en) | Medicine for treating senile dementia and preparing process thereof | |
| CN1507894A (en) | Medicine for treating gastrointestinal summer damp cold and preparing method thereof | |
| CN1672719A (en) | Application of fleece flower root in preparing medicine for treating fatty liver | |
| CN1686406A (en) | Compound quassia weed injection and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: JURIDICAL PERSON PHARMACEUTICAL INDUSTRIAL TECHNOL Free format text: FORMER NAME OR ADDRESS: PHARMACEUTICAL INDUSTRY AND TECHNOLOGY DEVELOPMENT CENTER |
|
| CP03 | Change of name, title or address |
Address after: Xi Taipei County of Taiwan province Zhenkang Ning street 169 Lane 101 Building No. 5 Patentee after: Medical & Pharm Ind Tech & Dev Address before: Xi Taipei County of Taiwan province Zhenkang Ning street 169 Lane 101 Building No. 5 Patentee before: Pharmaceutical Industry and Technology Development Center |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061018 |